Original Research
Published on 13 May 2026
Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan
in Headache and Neurogenic Pain
- 433 views